These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 14974951)

  • 1. Recovery from pure red cell aplasia caused by anti-erythropoietin antibodies after kidney transplantation.
    Snanoudj R; Beaudreuil S; Arzouk N; Jacq D; Casadevall N; Charpentier B; Durrbach A
    Am J Transplant; 2004 Feb; 4(2):274-7. PubMed ID: 14974951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case report: Dynamic antibody monitoring in a case of anti-recombinant human erythropoietin-mediated pure red cell aplasia with prolonged course after kidney transplantation.
    Chen XM; Li H; Wu Y; Wang LL; Bai YJ; Shi YY
    Front Immunol; 2022; 13():1049444. PubMed ID: 36524109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pure red cell aplasia and anti-erythropoietin antibodies in patients on hemodialysis: a report of two cases and a literature review.
    Lacreta G; Bucharles SGE; Sevignani G; Riella MC; Nascimento MMD
    J Bras Nefrol; 2019; 41(1):145-151. PubMed ID: 30160771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pure red cell aplasia induced by anti-erythropoietin antibodies, well-controlled with tacrolimus.
    Hashimoto K; Harada M; Kamijo Y
    Int J Hematol; 2016 Oct; 104(4):502-5. PubMed ID: 27338269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recovery of pure red-cell aplasia secondary to antierythropoietin antibodies after cessation of recombinant human erythropoietin.
    Panchapakesan U; Austin SK; Shafransky A; Lawrence JA; Savdie E
    Intern Med J; 2003; 33(9-10):468-71. PubMed ID: 14511202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pure red cell aplasia (PRCA) induced by anti-EPO antibodies: epidemiology, diagnosis and treatment].
    Janda K; Kraśniak A; Krzanowski M; Sułowicz W
    Przegl Lek; 2010; 67(3):187-91. PubMed ID: 20687383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cross-sectional immunosurveillance study of anti-EPO antibody levels in CRF patients receiving epoetin alfa in 5 Ontario Renal Centers.
    Wu G; Wadgymar A; Wong G; Ting R; Nathoo B; Mendelssohn D; Pandeya S; Sapir D; Tam P
    Am J Kidney Dis; 2004 Aug; 44(2):264-9. PubMed ID: 15264184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 46-Year-Old Thai Woman with Secondary Acquired Pure Red Cell Aplasia Due to Treatment with Recombinant Erythropoietin While on Dialysis for End-Stage Renal Disease Who Recovered Following ABO-Incompatible Kidney Transplantation.
    Kitpermkiat R; Thotsiri S; Arpornsujaritkun N; Sangkum P; Chantrathammachart P; Kitpoka P; Thammanichanond D; Virankabutra T; Kantachuvesiri S
    Am J Case Rep; 2022 Jul; 23():e935451. PubMed ID: 35842751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-mediated pure red cell aplasia related with epoetin-beta pegol (C.E.R.A.) as an erythropoietic agent: case report of a dialysis patient.
    Shingu Y; Nakata T; Sawai S; Tanaka H; Asai O; Tamagaki K; Nakatani K
    BMC Nephrol; 2020 Jul; 21(1):275. PubMed ID: 32664894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model.
    Woodburn KW; Fan Q; Winslow S; Chen MJ; Mortensen RB; Casadevall N; Stead RB; Schatz PJ
    Exp Hematol; 2007 Aug; 35(8):1201-8. PubMed ID: 17662888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-erythropoietin antibodies followed by endogenous erythropoietin production in a dialysis patient.
    Mattison P; Upadhyay K; Wilcox JE; Moudgil A; Silverstein DM
    Pediatr Nephrol; 2010 May; 25(5):971-6. PubMed ID: 20091055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project.
    Bennett CL; Cournoyer D; Carson KR; Rossert J; Luminari S; Evens AM; Locatelli F; Belknap SM; McKoy JM; Lyons EA; Kim B; Sharma R; Costello S; Toffelmire EB; Wells GA; Messner HA; Yarnold PR; Trifilio SM; Raisch DW; Kuzel TM; Nissenson A; Lim LC; Tallman MS; Casadevall N
    Blood; 2005 Nov; 106(10):3343-7. PubMed ID: 16099877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pure red cell aplasia in patients treated with recombinant erythropoietin for anemia due to chronic renal disease].
    Miyazaki T; Obana T; Takasaki H; Tanaka M; Yamaji S; Fujimaki K; Fujita H; Kanamori H; Ishigatsubo Y
    Rinsho Ketsueki; 2007 May; 48(5):391-6. PubMed ID: 17571584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of recombinant erythropoietin (EPO) hyporesponse, EPO-associated antibodies, and pure red cell aplasia in dialysis patients.
    Kharagjitsingh AV; Korevaar JC; Vandenbroucke JP; Boeschoten EW; Krediet RT; Daha MR; Dekker FW;
    Kidney Int; 2005 Sep; 68(3):1215-22. PubMed ID: 16105053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment of anti-erythropoietin antibody-mediated pure red cell aplasia with low-dose prednisolone.
    Aoki K; Ono Y; Tabata S; Matsushita A; Ishikawa T
    Int J Hematol; 2013 Feb; 97(2):272-4. PubMed ID: 23355260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiepoetin antibody-related pure red cell aplasia: successful remission with cessation of recombinant erythropoietin alone.
    Katagiri D; Shibata M; Katsuki T; Masumoto S; Katsuma A; Minami E; Hoshino T; Inoue T; Tada M; Hinoshita F
    Clin Exp Nephrol; 2010 Oct; 14(5):501-5. PubMed ID: 20652821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged course of pure red cell aplasia after erythropoietin therapy.
    Nigg L; Schanz U; Ambühl PM; Fehr J; Bachli EB
    Eur J Haematol; 2004 Nov; 73(5):376-9. PubMed ID: 15458518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Early onset of anti- erythropoietin antibody-mediated pure red cell aplasia after commencement of subcutaneous administration of epoetin-β].
    Tanaka A; Tsukada J; Morimoto H; Katsuragi T; Nakanishi T; Watanabe S; Hirase N; Motomura S
    Rinsho Ketsueki; 2012 Jan; 53(1):110-2. PubMed ID: 22374534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parvovirus B19 (B19) and cytomegalovirus (CMV) infections and anti-erythropoietin (anti-EPO) antibodies in patients on dialysis hyporesponsive to erythropoietin therapy.
    Alves MT; Vilaça SS; Godoi LC; Rezende Júnior L; Carvalho Md; Silva Fde S; Guimarães FL; Fernandes AP; Dusse LM; Gomes KB
    Clin Chim Acta; 2014 Apr; 431():52-7. PubMed ID: 24513539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roxadustat Improves Erythropoietin Antibody-Mediated Pure Red Cell Aplasia in a Patient with Hemodialysis.
    Li S; Chen X; Hu P; Wu S; Ma J; Li Z; Wu X; Wen F; Fu X; Feng Z; Tao Y; Li B; Fu L; Huang R; He C; Shi W; Liang X; Liu S
    Blood Purif; 2022; 51(2):189-192. PubMed ID: 34500449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.